Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Forrest

Showing results (21-30 of 177) with videos related to

Pageof 18
Sort By:
The Pediatric Infectious Disease Journal|October 27, 2010
Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infectionJohn S Bradley, Samira Merali Garonzik, Alan Forrest, et al.
Pharmacotherapy|May 14, 2003
A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonatesRobert DiCenzo, Alan Forrest, Judianne C Slish, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2003
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosaJoseph A Paladino, Jenna L Sunderlin, Alan Forrest, et al.
Journal of Clinical Pharmacology|August 20, 2004
Sex-related differences in the pharmacokinetics of oral ciprofloxacinBrian R Overholser, Michael B Kays, Alan Forrest, et al.
Proceedings. Biological Sciences|June 4, 2010
Nucleotide diversity in Silene latifolia autosomal and sex-linked genesSuo Qiu, Roberta Bergero, Alan Forrest, et al.
Journal of Clinical Pharmacology|June 5, 2002
Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racematePatrick F Smith, Alan Forrest, John M Adams, et al.
The Journal of Antimicrobial Chemotherapy|December 4, 2002
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycinPamela A Moise, Alan Forrest, Mary C Birmingham, et al.
Chest|October 16, 2002
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumoniaJoseph A Paladino, Larry D Gudgel, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacinAlison K Meagher, Alan Forrest, Axel Dalhoff, et al.
Clinical Pharmacokinetics|October 29, 2004
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsPamela A Moise-Broder, Alan Forrest, Mary C Birmingham, et al.
Pageof 18

Showing results (21-30 of 177) with videos related to

Sort By:
Pageof 18
The Pediatric Infectious Disease Journal|October 27, 2010
Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infectionJohn S Bradley, Samira Merali Garonzik, Alan Forrest, et al.
Pharmacotherapy|May 14, 2003
A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonatesRobert DiCenzo, Alan Forrest, Judianne C Slish, et al.
The Journal of Antimicrobial Chemotherapy|July 31, 2003
Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosaJoseph A Paladino, Jenna L Sunderlin, Alan Forrest, et al.
Journal of Clinical Pharmacology|August 20, 2004
Sex-related differences in the pharmacokinetics of oral ciprofloxacinBrian R Overholser, Michael B Kays, Alan Forrest, et al.
Proceedings. Biological Sciences|June 4, 2010
Nucleotide diversity in Silene latifolia autosomal and sex-linked genesSuo Qiu, Roberta Bergero, Alan Forrest, et al.
Journal of Clinical Pharmacology|June 5, 2002
Effect of food on the pharmacokinetics of (-) and (+) dOTC when administered as an oral racematePatrick F Smith, Alan Forrest, John M Adams, et al.
The Journal of Antimicrobial Chemotherapy|December 4, 2002
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycinPamela A Moise, Alan Forrest, Mary C Birmingham, et al.
Chest|October 16, 2002
Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumoniaJoseph A Paladino, Larry D Gudgel, Alan Forrest, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacinAlison K Meagher, Alan Forrest, Axel Dalhoff, et al.
Clinical Pharmacokinetics|October 29, 2004
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infectionsPamela A Moise-Broder, Alan Forrest, Mary C Birmingham, et al.
Pageof 18